CRAIG MUIR

Craig Muir stands as a distinguished Partner at Third Rock Ventures, a premier venture capital firm renowned for its unique approach to building groundbreaking life science companies. At Third Rock Ventures, Craig is instrumental in the firm's core mission: the creation, incubation, and strategic investment in innovative biopharmaceutical enterprises. His work encompasses the entire lifecycle of new company formation, from identifying nascent scientific discoveries with transformative potential to nurturing these concepts into robust, patient-focused organizations.

Craig's investment focus is deeply rooted in the cutting edge of life sciences. He seeks out opportunities that promise to deliver significant therapeutic solutions, particularly in areas where unmet medical needs are profound. His expertise spans various therapeutic modalities and disease areas, always with an eye towards scientific rigor and clinical impact. He is passionate about translating complex biological insights into tangible medicines that can improve human health. This involves a hands-on approach to company building, working closely with scientific founders and management teams to shape strategy, develop pipelines, and navigate the intricate landscape of drug development.

Prior to joining Third Rock Ventures in 2017, Craig honed his skills and deepened his understanding of biotech innovation at Flagship Pioneering, where he served in various roles including Principal, Senior Associate, and Associate. This experience provided him with invaluable insights into the process of de novo company creation and venture capital investment within the life sciences sector. His foundational scientific training includes a postdoctoral fellowship at Harvard Medical School and Massachusetts General Hospital, further solidifying his expertise in biological research.

Academically, Craig Muir holds a Ph.D. in Biological Engineering from the Massachusetts Institute of Technology (MIT), a testament to his interdisciplinary approach to scientific problem-solving. He also earned a B.S. in Chemical Engineering from the University of California, Berkeley. This robust educational background equips him with a unique blend of engineering principles and biological understanding, crucial for evaluating and guiding complex scientific ventures.

Craig's commitment to fostering innovation is evident through his involvement with several portfolio companies. He currently serves on the Board of Directors for Celsius Therapeutics, Flare Therapeutics, and Terremoto Biosciences, actively contributing to their strategic growth and development. His past involvement includes significant contributions to companies such as Cedilla Therapeutics, Ensoma, and Kallyope. Through these roles, Craig Muir continues to drive the advancement of novel therapies, reinforcing Third Rock Ventures' reputation as a leader in life science venture creation and investment.